Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

BACKGROUND: Immune checkpoint blockade (ICB) using anti-CTLA-4 and anti-PD-1/PD-L1 has revolutionized the treatment of advanced cancer. However, ICB is effective for only a small fraction of patients, and biomarkers such as expression of PD-L1 in tumor or serum levels of CXCL11 have suboptimal sensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Koguchi, Yoshinobu, Iwamoto, Noriko, Shimada, Takashi, Chang, Shu-Ching, Cha, John, Curti, Brendan D, Urba, Walter J, Piening, Brian D, Redmond, William L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499328/
https://www.ncbi.nlm.nih.gov/pubmed/34620702
http://dx.doi.org/10.1136/jitc-2021-002663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499328/
https://www.ncbi.nlm.nih.gov/pubmed/34620702
http://dx.doi.org/10.1136/jitc-2021-002663

Ejemplares similares